Going mobile: FDA clears world's first bedside MRI scanner-on-wheels

Hyperfine's portable MRI features permanent magnets that require no extra power or cooling, with the whole system running off a standard wall outlet to produce a brain scan. (Hyperfine)

The FDA has cleared the world’s first portable MRI system, designed to be wheeled to a hospital bedside for scanning a patient’s head and brain.

Developed by Hyperfine Research for people age two and older, the point-of-care imaging system weighs about one-tenth that of a conventional, fixed MRI system. About three feet wide and five feet tall, the device fits in an elevator and runs off an everyday power outlet to create both clinical contrast images and 3D renders.

“More than 40 years after its first use, MRI remains a marvel. Unfortunately, it also remains inaccessible,” Hyperfine Chief Medical Officer Khan Siddiqui said in a statement. “It’s time that MRI made the jump to point of need just like X-ray and ultrasound have before it.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Going beyond that, nearly 90% of the world has no access to MRI at all,” Siddiqui added. “With the FDA’s decision, we are now ready to rewrite the rules of MRI accessibility.”

RELATED: FDA clears new Siemens MRI with optional in-bore 'infotainment' system

Hyperfine estimates its open-design system will also cost about 20 times less—controlled through a wireless tablet, it does not require trained technicians, shielded electronics or separate hospital facilities.

It also features ordinary permanent magnets that require no power or cooling, producing an image using low-power radio waves and magnetic fields. Now, with a 510(k) clearance in hand, the company plans to begin shipments this summer.

“We assembled an astounding team, and they took the 10 million-fold improvement in computing power since MRI was invented and the best of the billions invested in green electronics and built something astonishing, something disruptive,” said Jonathan Rothberg, Hyperfine’s founder and chairman.

Additionally, Hyperfine is working to develop artificial intelligence and deep learning software to reconstruct images and assist in diagnosis.

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.